Sleep Apnea Endophenotypes: One Size Does Not Fit All

睡眠呼吸暂停内表型:一种方法并不适用于所有情况

基本信息

  • 批准号:
    10686814
  • 负责人:
  • 金额:
    $ 66.34万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-05-15 至 2026-04-30
  • 项目状态:
    未结题

项目摘要

Project Summary OSA is defined by repetitive collapse of the upper airway, a process which leads to transient hypoxemia and arousals from sleep, and is associated with various cardiovascular, metabolic, and neurocognitive consequences. OSA is the most common respiratory disorder, affecting roughly 10% of middle aged men and women in the USA and up to 1 billion globally. Although continuous positive airway pressure (PAP) is an efficacious therapy, it is not always well tolerated and adherence is less than ideal. OSA is increasingly recognized as a multifactorial disorder that can occur in different people for different reasons, not only due to anatomical predisposition (collapsibility of the upper airway), but also related to low arousal threshold (wake up too easily), dysfunction in upper airway dilator muscles and instability in ventilatory control. Through careful measurement of these underlying factors and the symptoms experienced in OSA, this proposal seeks to understand how different mechanisms underlying OSA – endotypes – lead to different symptoms or consequences – phenotypes. These different phenotypes range from having no appreciable symptoms, to falling asleep at the wheel, to experiencing cardiometabolic consequences. Additionally, addressing the underlying cause might be useful to personalize therapy, to predict adherence to PAP, and to understand which symptoms will or will not improve with long term PAP therapy. A major challenge in clinical practice is understanding whether particular symptoms are due to OSA, and whether these symptoms will improve with treatment. Moreover, we are currently struggling to find alternative therapies for OSA which will likely depend on underlying mechanism. Similarly, we do not currently know which patients to put into clinical trials since it seems unlikely that, e.g., all OSA patients will have cardiovascular benefits to PAP therapy since not all are at risk of heart disease. Our goals are 1) To understand the contribution of the underlying cause, or endotype, of OSA to the symptoms experienced by people with OSA, 2) To elucidate how the endotype predicts response to non CPAP therapies, such as oxygen or sedative hypnotics, and 3) To define how underlying endotype (mechanism) mediates changes in phenotype (clinical manifestations of disease) with treatment of OSA. Ultimately we hope that our efforts will advance the OSA field and help to alleviate suffering or reduce/prevent disease burden.
项目摘要 阻塞性睡眠呼吸暂停的定义是上呼吸道的反复塌陷,这是一个导致短暂低氧血症的过程, 从睡眠中唤醒,并与各种心血管,代谢和神经认知有关 后果OSA是最常见的呼吸系统疾病,影响大约10%的中年男性, 美国和全球多达10亿的女性。虽然持续气道正压通气(PAP)是一种有效的治疗方法, 然而,尽管它是一种有效的治疗方法,但并不总是耐受良好,并且依从性也不理想。OSA越来越多 被认为是一种多因素的疾病,可以发生在不同的人,不同的原因,不仅是由于 解剖学倾向(上呼吸道的可呼吸性),但也与低唤醒阈值(唤醒)有关 太容易)、上呼吸道扩张肌功能障碍和呼吸控制不稳定。通过仔细 为了测量这些潜在因素和OSA中经历的症状,该提案旨在 了解OSA的不同机制-内型-如何导致不同的症状或 后果-表型。这些不同的表型从没有明显的症状, 在开车时睡着,到经历心脏代谢的后果。此外,解决 潜在原因可能有助于个性化治疗,预测PAP的依从性,并了解 长期PAP治疗可改善或不改善症状。临床实践中的一个主要挑战是 了解特定的症状是否是由于OSA,以及这些症状是否会改善, 治疗此外,我们目前正在努力寻找OSA的替代疗法,这可能取决于 潜在机制同样,我们目前也不知道哪些患者应该进行临床试验,因为 不太可能,例如,PAP治疗对所有OSA患者都有心血管益处,因为并非所有OSA患者都有 心脏病我们的目标是:1)了解OSA的潜在病因或内型对 2)为了阐明内型如何预测对非阻塞性睡眠呼吸暂停综合征的反应, CPAP治疗,如氧气或镇静催眠药,以及3)定义潜在的内型(机制) 通过OSA的治疗介导表型(疾病的临床表现)的变化。最终我们希望 我们的努力将推动OSA领域的发展,并有助于减轻痛苦或减少/预防疾病负担。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Atul Malhotra其他文献

Atul Malhotra的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Atul Malhotra', 18)}}的其他基金

The cardiovascular consequences of sleep apnea plus COPD (Overlap syndrome)
睡眠呼吸暂停加慢性阻塞性肺病(重叠综合征)对心血管的影响
  • 批准号:
    10733384
  • 财政年份:
    2023
  • 资助金额:
    $ 66.34万
  • 项目类别:
VentNet: A Real-Time Multimodal Data Integration Model for Prediction of Respiratory Failure in Patients with COVID-19
VentNet:用于预测 COVID-19 患者呼吸衰竭的实时多模式数据集成模型
  • 批准号:
    10367298
  • 财政年份:
    2022
  • 资助金额:
    $ 66.34万
  • 项目类别:
VentNet: A Real-Time Multimodal Data Integration Model for Prediction of Respiratory Failure in Patients with COVID-19
VentNet:用于预测 COVID-19 患者呼吸衰竭的实时多模式数据集成模型
  • 批准号:
    10573201
  • 财政年份:
    2022
  • 资助金额:
    $ 66.34万
  • 项目类别:
Sleep Apnea Endophenotypes: One Size Does Not Fit All
睡眠呼吸暂停内表型:一种方法并不适用于所有情况
  • 批准号:
    10084644
  • 财政年份:
    2021
  • 资助金额:
    $ 66.34万
  • 项目类别:
Sleep Apnea Endophenotypes: One Size Does Not Fit All
睡眠呼吸暂停内表型:一种方法并不适用于所有情况
  • 批准号:
    10404911
  • 财政年份:
    2021
  • 资助金额:
    $ 66.34万
  • 项目类别:
Underlying mechanisms of obesity-induced obstructive sleep apnea
肥胖引起的阻塞性睡眠呼吸暂停的潜在机制
  • 批准号:
    10404650
  • 财政年份:
    2020
  • 资助金额:
    $ 66.34万
  • 项目类别:
Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease
阻塞性睡眠呼吸暂停对阿尔茨海默病的发展很重要吗
  • 批准号:
    9974144
  • 财政年份:
    2020
  • 资助金额:
    $ 66.34万
  • 项目类别:
Underlying mechanisms of obesity-induced obstructive sleep apnea
肥胖引起的阻塞性睡眠呼吸暂停的潜在机制
  • 批准号:
    10636633
  • 财政年份:
    2020
  • 资助金额:
    $ 66.34万
  • 项目类别:
Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease
阻塞性睡眠呼吸暂停对阿尔茨海默病的发展很重要吗
  • 批准号:
    10615709
  • 财政年份:
    2020
  • 资助金额:
    $ 66.34万
  • 项目类别:
Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease
阻塞性睡眠呼吸暂停对阿尔茨海默病的发展很重要吗
  • 批准号:
    10398186
  • 财政年份:
    2020
  • 资助金额:
    $ 66.34万
  • 项目类别:

相似海外基金

An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 66.34万
  • 项目类别:
    Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 66.34万
  • 项目类别:
    Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 66.34万
  • 项目类别:
    Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 66.34万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 66.34万
  • 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 66.34万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 66.34万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 66.34万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 66.34万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 66.34万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了